Rabies literature review - Literature review on the progress of the 2018 Vaccine Investment Strategy (VIS)

In 2018, the Gavi Board approved the inclusion of Rabies Post-Exposure Prophylaxis (PEP) into the portfolio of vaccines to be funded in the 2021-2025 strategic period. Various challenges were identified in relation to its operationalisation leading to the elaboration of the 2018 VIS Rabies learning agenda under the principle of using an appropriate partnership structure to ensure complementarity between donor investments in human and animal rabies control. The new vaccine programs and learning agenda approved under 2018 VIS were paused in 2021 due to the COVID-19 pandemic, and approval for their implementation was given in May 2023. As a result of an initial research agenda now considered as obsolete, Gavi mandates Swiss TPH to undertake a scoping review to confirm the extent to which the learning questions listed in 2018 have indeed been answered and propose new evidence gaps that Gavi can focus on for learning.
The objective of this assignment is to provide evidence to Gavi on the status of the literature in relation to IBCM implementation and PEP challenges to inform upcoming evidence production initiatives.

Involved Regions: Africa
Involved Countries: Switzerland

Contact